Fig 1: Spearman correlation analysis between key clinical indicators and protein expression patterns. (a) Heatmap of Spearman correlations between key core proteins and VAS, ODI, JOA scores before and after treatment in the experimental group (color intensity indicates correlation strength; red denotes positive correlation, blue denotes negative correlation; “*” indicates p < 0.05, “**” indicates p < 0.01). (b) Correlation analysis and group comparisons of core proteins CXCL12, ACTN1, CXCR4, and CCN2 with VAS scores. (c) Correlation analysis and group comparisons of core proteins CXCL12, ACTN1, CXCR4, and CCN2 with ODI scores. (d) Correlation analysis and group comparisons of core proteins CXCL12, ACTN1, CXCR4, and CCN2 with JOA scores.
Fig 2: ELISA-based validation of core proteins CXCL12, CXCR4, CCN2, and ACTN1 in plasma samples from the H, LDH, and Acu groups. (a) Plasma CXCL12 levels and group comparisons among the H, LDH, and Acu groups. (b) Plasma CXCR4 levels and group comparisons among the H, LDH, and Acu groups. (c) Plasma CCN2 levels and group comparisons among the H, LDH, and Acu groups. (d) Plasma ACTN1 levels and group comparisons among the H, LDH, and Acu groups. Statistical significance was determined using the Mann–Whitney U test (H vs. LDH) and the Wilcoxon signed-rank test (LDH vs. Acu). p < 0.05 was considered statistically significant.
Supplier Page from Fine Biotech Co., Ltd. for Human ACTN1 (Alpha-actinin-1) ELISA Kit